NasdaqGM - Nasdaq Real Time Price USD

Harvard Bioscience, Inc. (HBIO)

3.5900 +0.0300 (+0.84%)
As of 1:48 PM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
112,250.0000
112,250.0000
113,335.0000
118,904.0000
102,100.0000
Cost of Revenue
46,179.0000
46,179.0000
52,516.0000
51,252.0000
44,059.0000
Gross Profit
66,071.0000
66,071.0000
60,819.0000
67,652.0000
58,041.0000
Operating Expense
64,177.0000
64,177.0000
67,985.0000
65,586.0000
57,820.0000
Operating Income
1,894.0000
1,894.0000
-7,166.0000
2,066.0000
221.0000
Net Non Operating Interest Income Expense
-3,591.0000
-3,591.0000
-2,548.0000
-1,540.0000
-4,831.0000
Other Income Expense
-859.0000
-859.0000
535.0000
-666.0000
-2,682.0000
Pretax Income
-2,556.0000
-2,556.0000
-9,179.0000
-140.0000
-7,292.0000
Tax Provision
859.0000
859.0000
337.0000
148.0000
518.0000
Net Income Common Stockholders
-3,415.0000
-3,415.0000
-9,516.0000
-288.0000
-7,810.0000
Diluted NI Available to Com Stockholders
-3,415.0000
-3,415.0000
-9,516.0000
-288.0000
-7,810.0000
Basic EPS
-0.08
-0.08
-0.23
-0.01
-0.20
Diluted EPS
-0.08
-0.08
-0.23
-0.01
-0.20
Basic Average Shares
42,157.0000
42,420.0000
41,413.0000
40,343.0000
38,640.0000
Diluted Average Shares
42,157.0000
42,420.0000
41,413.0000
40,343.0000
38,640.0000
Total Operating Income as Reported
1,894.0000
1,894.0000
-6,933.0000
2,066.0000
221.0000
Total Expenses
110,356.0000
110,356.0000
120,501.0000
116,838.0000
101,879.0000
Net Income from Continuing & Discontinued Operation
-3,415.0000
-3,415.0000
-9,516.0000
-288.0000
-7,810.0000
Normalized Income
-2,915.7200
-2,915.7200
-9,700.0700
-288.0000
-6,440.5200
Interest Expense
3,591.0000
3,591.0000
2,548.0000
1,540.0000
4,831.0000
Net Interest Income
-3,591.0000
-3,591.0000
-2,548.0000
-1,540.0000
-4,831.0000
EBIT
1,035.0000
1,035.0000
-6,631.0000
1,400.0000
-2,461.0000
EBITDA
8,033.0000
8,033.0000
944.0000
9,021.0000
5,171.0000
Reconciled Cost of Revenue
44,706.0000
44,706.0000
51,063.0000
49,471.0000
42,137.0000
Reconciled Depreciation
6,998.0000
6,998.0000
7,575.0000
7,621.0000
7,632.0000
Net Income from Continuing Operation Net Minority Interest
-3,415.0000
-3,415.0000
-9,516.0000
-288.0000
-7,810.0000
Total Unusual Items Excluding Goodwill
-632.0000
-632.0000
233.0000
--
-1,876.0000
Total Unusual Items
-632.0000
-632.0000
233.0000
--
-1,876.0000
Normalized EBITDA
8,665.0000
8,665.0000
711.0000
9,021.0000
7,047.0000
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0003
0.0003
Tax Effect of Unusual Items
-132.7200
-132.7200
48.9300
--
-506.5200
12/31/2020 - 3/19/2001

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ANGO AngioDynamics, Inc.
5.83
+0.78%
 
UTMD Utah Medical Products, Inc.
66.00
-0.44%
 
POCI Precision Optics Corporation, Inc.
5.58
-1.35%
 
OSUR OraSure Technologies, Inc.
5.34
+1.43%
 
ATR AptarGroup, Inc.
144.73
+3.25%
 
KRMD KORU Medical Systems, Inc.
2.1800
-0.46%
 
NEPH Nephros, Inc.
2.1550
+0.70%
 
INFU InfuSystem Holdings, Inc.
8.00
+5.12%
 
ANIK Anika Therapeutics, Inc.
25.57
-0.04%
 
EKSO Ekso Bionics Holdings, Inc.
1.1900
-7.03%